List view / Grid view
25 September 2018 | By Mike Stones
The new hub is designed to speed the response to deadly pandemics by improving the development and manufacturing of vaccines – particularly in low- and middle-income countries...
1 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A new study has found a blood test for cancer DNA could predict if a woman is responding to the new breast cancer drug palbociclib, months earlier than current tests...
4 January 2018 | By Beatriz Faro - Pfizer
For Pfizer, putting patients first guides its actions, informs its strategic decisions and unifies colleagues in every region and function across the company. Beatriz Faro, Regional President, Internal Medicine, International Developed Markets at Pfizer, explains how the company’s philosophy is taking the business forward...
2 January 2018 | By Christof Hohne
Christof Hohne, partner at patent law firm EIP, discusses second medical use claims and compulsory licences...
21 December 2017 | By European Pharmaceutical Review
European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.
4 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has approved Mylotarg for the treatment of adults with newly diagnosed acute myeloid leukaemia whose tumours express the CD33 antigen...
25 July 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Major market players across the US are upping investments in research to innovate on treatment methods and improve ophthalmic drugs action...
13 July 2017 | By Niamh Marriott (European Pharmaceutical Review)
NICE has approved adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer) and ustekinumab (Stelara, Janssen) for treating plaque psoriasis in children...
16 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
The FDA has approved BioMarin Pharmaceutical’s bulk biologics manufacturing plant, located in Cork, Ireland for production of the formulated bulk substance.
15 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
The FDA has granted fast track designation for Pfizer and Eli Lilly’s tanezumab for the treatment of chronic pain in patients with osteoarthritis...
6 June 2017 | By Niamh Marriott, Junior Editor
Regulatory submissions to the EMA and FDA for a single-tablet, two-drug regimen of dolutegravir & rilpivirine for the maintenance treatment of HIV...
22 May 2017 | By Niamh Marriott, Junior Editor
Pfizer have announced an extension of their collaboration to further broaden access to Pfizer’s all-in-one injectable contraceptive...
17 May 2017 | By Niamh Marriott, Junior Editor
Sangamo and Pfizer have announced a global collaboration and license agreement for the development of gene therapy programs for Haemophilia A...
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
25 April 2017 | By Niamh Marriott, Junior Editor
Pfizer's results show patients diagnosed with hospital-acquired pneumonia (HAP) treated with Zavicefta or Meropenem experienced comparable rates of cure...
Follow: